60% no disease progression in 5 years with Pfizer's lung cancer drug Lorlatinib in late-stage trial versus 8% with crizotinib.
Pfizer's lung cancer drug, Lorlatinib (Lorbrena), has shown promising long-term results in a late-stage trial, with 60% of patients receiving the treatment experiencing no disease progression after five years. This compares to 8% of patients treated with another standard treatment, crizotinib. The drug, which targets ALK-positive advanced non-small cell lung cancer, could potentially help establish it as the new standard treatment for this form of cancer.
May 31, 2024
25 Articles